The History of Cancer
The History of Cancer
The History of Cancer
2345
The growth in our knowledge of cancer biology has led to remarkable progress in
cancer prevention, early detection, and treatment. Scientists have learned more about
cancer in the last 2 decades than had been learned in all the centuries preceding. This
doesn’t change the fact, however, that all scientific knowledge is based on the
knowledge already acquired by the hard work and discovery of our predecessors – and
we know that there’s still a lot more to learn
1
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Human beings and other animals have had cancer throughout recorded history. So it’s
no surprise that from the dawn of history people have written about cancer. Some of the
earliest evidence of cancer is found among fossilized bone tumors, human mummies in
ancient Egypt, and ancient manuscripts. Growths suggestive of the bone cancer called
osteosarcoma have been seen in mummies. Bony skull destruction as seen in cancer of
the head and neck has been found, too.
Our oldest description of cancer (although the word cancer was not used) was
discovered in Egypt and dates back to about 3000 BC. It’s called the Edwin Smith
Papyrus and is a copy of part of an ancient Egyptian textbook on trauma surgery. It
describes 8 cases of tumors or ulcers of the breast that were removed by cauterization
with a tool called the fire drill. The writing says about the disease, “There is no
treatment.”
The origin of the word cancer is credited to the Greek physician Hippocrates (460-370
BC), who is considered the “Father of Medicine.” Hippocrates used the terms carcinos
and carcinoma to describe non-ulcer forming and ulcer-forming tumors. In Greek, these
words refer to a crab, most likely applied to the disease because the finger-like
spreading projections from a cancer called to mind the shape of a crab. The Roman
physician, Celsus (25 BC - 50 AD), later translated the Greek term into cancer, the Latin
word for crab. Galen (130-200 AD), another Greek physician, used the word oncos
(Greek for swelling) to describe tumors. Although the crab analogy of Hippocrates and
Celsus is still used to describe malignant tumors, Galen’s term is now used as a part of
the name for cancer specialists – oncologists.
2
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
During the Renaissance, beginning in the 15th century, scientists developed greater
understanding of the human body. Scientists like Galileo and Newton began to use the
scientific method, which later was used to study disease. Autopsies, done by Harvey
(1628), led to an understanding of the circulation of blood through the heart and body
that had until then been a mystery.
In 1761, Giovanni Morgagni of Padua was the first to do something which has become
routine today – he did autopsies to relate the patient’s illness to pathologic findings after
death. This laid the foundation for scientific oncology, the study of cancer.
The famous Scottish surgeon John Hunter (1728-1793) suggested that some cancers
might be cured by surgery and described how the surgeon might decide which cancers
to operate on. If the tumor had not invaded nearby tissue and was “moveable,” he said,
“There is no impropriety in removing it.”
A century later the development of anesthesia allowed surgery to flourish and classic
cancer operations such as the radical mastectomy were developed.
The 19th century saw the birth of scientific oncology with use of the modern microscope
in studying diseased tissues. Rudolf Virchow, often called the founder of cellular
pathology, provided the scientific basis for the modern pathologic study of cancer. As
Morgagni had linked autopsy findings seen with the unaided eye with the clinical course
of illness, so Virchow correlated microscopic pathology to illness.
This method not only allowed a better understanding of the damage cancer had done,
but also aided the development of cancer surgery. Body tissues removed by the
surgeon could now be examined and a precise diagnosis could be made. The
pathologist could also tell the surgeon whether the operation had completely removed
the cancer.
Hyperlinks
1. www.cancer.org/cancer/understanding-cancer/what-is-cancer.html
2. www.cancer.org/cancer/types/osteosarcoma.html
References
3
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 1. Cancer.
2011;117(5):1097-1102.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 2. Cancer.
2011;117(12):2811-2820.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. Cancer.
2012;118(4):1155-1168.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. Cancer.
2012;118(20):4914-4928.
4
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
From the earliest times, physicians have puzzled over the causes of cancer. Ancient
Egyptians blamed cancers on the gods.
Humoral theory
Hippocrates believed that the body had 4 humors (body fluids): blood, phlegm, yellow
bile, and black bile. When the humors were balanced, a person was healthy. The belief
was that too much or too little of any of the humors caused disease. An excess of black
bile in various body sites was thought to cause cancer. This theory of cancer was
passed on by the Romans and was embraced by the influential doctor Galen’s medical
teaching, which remained the unchallenged standard through the Middle Ages for over
1,300 years. During this period, the study of the body, including autopsies, was
prohibited for religious reasons, which limited progress of medical knowledge.
Lymph theory
Among theories that replaced the humoral theory of cancer was the formation of cancer
by another body fluid, lymph. Life was believed to consist of continuous and appropriate
movement of the fluid parts of the body through the solid parts. Of all the fluids, the
most important were blood and lymph. Stahl and Hoffman theorized that cancer was
composed of fermenting and degenerating lymph, varying in density, acidity, and
alkalinity. The lymph theory gained rapid support. John Hunter, the Scottish surgeon
from the 1700s, agreed that tumors grow from lymph constantly thrown out by the
blood.
Blastema theory
Virchow proposed that chronic irritation was the cause of cancer, but he believed
incorrectly that cancers “spread like a liquid.” In the 1860s, German surgeon, Karl
Thiersch, showed that cancers metastasize through the spread of malignant cells and
5
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Trauma theory
Despite advances in the understanding of cancer, from the late 1800s until the 1920s,
trauma was thought by some to cause cancer. This belief was maintained despite the
failure of injury to cause cancer in experimental animals.
Throughout the 17th and 18th centuries, some believed that cancer was contagious. In
fact, the first cancer hospital in France was forced to move from the city in 1779
because people feared cancer would spread throughout the city. Although human
cancer, itself, is not contagious, we now know that certain viruses, bacteria, and
parasites can increase a person’s risk of developing cancer.
Today we recognize and avoid many specific substances that cause cancer: coal tars
and their derivatives (like benzene), some hydrocarbons, aniline (a substance used to
make dyes), asbestos, and many others. Ionizing radiation from a variety of sources,
including the sun, is also known to cause cancer. To ensure the public’s safety, the
government has set safety standards for many substances, including benzene,
asbestos, hydrocarbons in the air, arsenic in drinking water, and radiation.
6
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
In 1911, Peyton Rous, at the Rockefeller Institute in New York, described a type of
cancer (sarcoma) in chickens caused by what later became known as the Rous
sarcoma virus. He was awarded the Nobel Prize for that work in 1968. Several viruses
are now linked to cancer in humans, for example:
● Long-standing infection with the hepatitis B or C viruses can lead to cancer of the
liver.
● One of the herpes viruses, the Epstein-Barr virus, causes infectious mononucleosis
and has been linked to non-Hodgkin lymphomas and nasopharyngeal cancer.
● People with human immunodeficiency virus (HIV) have greater increased risk of
developing several cancers, especially Kaposi sarcoma and non-Hodgkin
lymphoma.
● Human papilloma viruses (HPVs) have been linked to many cancers, especially
those of the cervix, vulva, vagina, anus, and penis. Some head and neck cancers
(mostly the tongue and tonsils) are linked to the high-risk types of HPV, too. Today
there are vaccines to help prevent HPV infection.
By the middle of the 20th century, scientists had the instruments they needed to work
on some of the complex problems of chemistry and biology that remained unsolved.
James Watson and Francis Crick, who received a Nobel Prize in 1962 for their work,
had discovered the exact chemical structure of DNA, the basic material in genes.
DNA was found to be the basis of the genetic code that gives orders to all cells. After
learning how to translate this code, scientists were able to understand how genes
worked and how they could be damaged by mutations (changes or mistakes in genes).
These modern techniques of chemistry and biology answered many complex questions
about cancer.
Scientists already knew that cancer could be caused by chemicals, radiation, and
viruses, and that sometimes cancer seemed to run in families. But as the understanding
of DNA and genes increased, they learned that it was the damage to DNA by chemicals
and radiation, or the introduction of new DNA sequences by viruses that often led to the
development of cancer. It became possible to pinpoint the exact site of the damage on a
7
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
specific gene.
Scientists discovered that sometimes defective genes are inherited, and sometimes
these inherited genes are defective at the points where certain chemicals also tend to
cause damage. In other words, most of the things that caused cancer (carcinogens)
caused genetic damage (mutations) that looked a lot like the mutations that could be
inherited and could result in the same types of cancer if more mutations were
introduced.
No matter which way the first mutation started (inborn or spontaneous), the cells that
grew from the mutated cells led to groups of abnormal cells (called clones, or duplicates
of the abnormal cell). The mutant clones evolved to even more malignant clones over
time, and the cancer progressed by more and more genetic damage and mutations. The
big difference between normal tissues and cancer is that normal cells with damaged
DNA die, while cancer cells with damaged DNA do not. The discovery of this critical
difference answered many questions that had troubled scientists for many years.
During the 1970s, scientists discovered 2 particularly important families of genes related
to cancer: oncogenes and tumor suppressor genes.
Oncogenes: These genes cause cells to grow out of control and become cancer cells.
They are formed by changes or mutations of certain normal genes of the cell called
proto-oncogenes. Proto-oncogenes are the genes that normally control how often a cell
divides and the degree to which it differentiates (or specializes in a specific function in
the body).
Tumor suppressor genes: These are normal genes that slow down cell division, repair
DNA errors, and tell cells when to die (a process known as apoptosis or programmed
cell death). When tumor suppressor genes don’t work properly, cells can grow out of
control, which can lead to cancer.
It may be helpful to think of a cell as a car. For it to work properly, there need to be
ways to control how fast it goes. A proto-oncogene normally functions in a way that is
similar to a gas pedal – it helps the cell grow and divide. An oncogene could be
compared to a gas pedal that is stuck down, which causes the cell to divide out of
control. A tumor suppressor gene is like the brake pedal on a car. It normally keeps the
cell from dividing too quickly just as a brake keeps a car from going too fast. When
something goes wrong with the gene, for example if a mutation causes it to stop
working, cell division can get out of control.
8
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Slowly, medical scientists are identifying the oncogenes and tumor suppressor genes
that are damaged by chemicals or radiation and those that, when inherited, can lead to
cancer. For example, the 1990s discovery of 2 genes that cause some breast cancers,
BRCA1 and BRCA2, is a step forward because these genes can be used to identify
people who have a higher risk of developing breast cancer.
Other genes have been discovered that are linked to cancers that run in families, such
as cancers of the colon, rectum, kidney, ovary, thyroid, pancreas, and skin melanoma.
Familial cancer is not nearly as common as spontaneous cancer (cancer that is caused
by DNA damage that starts during a person’s lifetime). Cancer linked to heredity is less
than 15% of all cancers. Still, it’s important to understand these cancers because with
continued research in genetics we may be able to identify more people at very high risk.
Hyperlinks
1. www.cancer.org/cancer/risk-prevention/infections.html
2. www.cancer.org/cancer/risk-prevention/tobacco.html
3. www.cancer.org/cancer/risk-prevention/chemicals/benzene.html
4. www.cancer.org/cancer/risk-prevention/chemicals/asbestos.html
5. www.cancer.org/cancer/risk-prevention/radiation-exposure.html
6. www.cancer.org/cancer/risk-prevention/chemicals/arsenic.html
7. www.cancer.org/cancer/types/liver-cancer.html
8. www.cancer.org/cancer/types/non-hodgkin-lymphoma.html
9. www.cancer.org/cancer/types/nasopharyngeal-cancer.html
10. www.cancer.org/cancer/risk-prevention/infections/hiv-infection-aids.html
11. www.cancer.org/cancer/types/kaposi-sarcoma.html
12. www.cancer.org/cancer/risk-prevention/infections/hpv.html
13. www.cancer.org/cancer/types/cervical-cancer.html
14. www.cancer.org/cancer/types/vulvar-cancer.html
15. www.cancer.org/cancer/types/vaginal-cancer.html
16. www.cancer.org/cancer/types/anal-cancer.html
17. www.cancer.org/cancer/types/penile-cancer.html
9
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
18. www.cancer.org/cancer/types/oral-cavity-and-oropharyngeal-cancer.html
19. www.cancer.org/cancer/understanding-cancer/genes-and-cancer.html
20. www.cancer.org/cancer/types/breast-cancer.html
21. www.cancer.org/cancer/types/colon-rectal-cancer.html
22. www.cancer.org/cancer/types/kidney-cancer.html
23. www.cancer.org/cancer/types/ovarian-cancer.html
24. www.cancer.org/cancer/types/thyroid-cancer.html
25. www.cancer.org/cancer/types/pancreatic-cancer.html
26. www.cancer.org/cancer/types/melanoma-skin-cancer.html
27. www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes.html
28. www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy.html
References
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 1. Cancer.
2011;117(5):1097-1102.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 2. Cancer.
2011;117(12):2811-2820.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. Cancer.
2012;118(4):1155-1168.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. Cancer.
2012;118(20):4914-4928.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
10
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
11
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Immoderate Use of Snuff. These first observations linking tobacco and cancer led
to epidemiologic research many years later (in the 1950s and early 1960s) which
showed that smoking causes lung cancer and led to the US Surgeon General’s
1964 report Smoking and Health.
Epidemiologists continue to search for factors that cause cancer (like tobacco use,
obesity, ultraviolet radiation), as well as those things that can help protect against
cancer (such as physical activity and a healthy diet). This research provides evidence to
guide public health recommendations and regulations.
As molecular biologists learn more about how factors cause or prevent cancer, this
information is used to study molecular epidemiology, which is the study of interactions
between genes and external factors.
Hyperlinks
1. www.cancer.org/cancer/types/cervical-cancer.html
2. www.cancer.org/cancer/types/breast-cancer.html
3. www.cancer.org/cancer/risk-prevention/infections.html
4. www.cancer.org/cancer/risk-prevention/chemicals.html
5. www.cancer.org/cancer/risk-prevention/tobacco.html
6. www.cancer.org/cancer/risk-prevention/diet-physical-activity/body-weight-and-
cancer-risk.html
7. www.cancer.org/cancer/risk-prevention/sun-and-uv/uv-radiation.html
8. www.cancer.org/cancer/risk-prevention/diet-physical-activity/acs-guidelines-
nutrition-physical-activity-cancer-prevention.html
References
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
12
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. Cancer.
2012;118(4):1155-1168.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. Cancer.
2012;118(20):4914-4928.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
Screening refers to tests used to find a disease, such as cancer, in people who do not
have any symptoms.
The first screening test to be widely used for cancer was the Pap test. The test was
developed by George Papanicolaou as a research method in understanding the
menstrual cycle. Papanicolaou soon recognized its potential for finding cervical cancer
early and presented his findings in 1923. At first, most doctors were skeptical, and it
was not until the American Cancer Society (ACS) promoted the test during the early
1960s that this test became widely used. Since that time, cervical cancer incidence and
mortality rates have decreased by more than 50% due to screening, which can detect
both cervical pre-cancers and cervical cancer at an early stage.
13
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Modern mammography methods were developed late in the 1960s and first officially
recommended by the ACS in 1976. The mammogram continues to be the most reliable
way to screen for breast cancer.
Current American Cancer Society guidelines include methods for early detection of
cervical, breast, colorectal, lung, and prostate cancers.
Proteomic methods are also being tested for cancer screening. For most types of
cancer, measuring the amount of one protein in the blood is not very good at finding
early cancers. But researchers are hopeful that comparing the relative amounts of many
proteins may be more useful, and that finding large amounts of certain proteins and less
of others can provide accurate, useful information about cancer treatment and its
outcomes. Proteins (and other types of molecules) are even found in exhaled breath,
which is now being tested to find out if it can show early signs of lung cancer. This is an
exciting area of research and early results in lung and colorectal cancer studies have
been promising.
Nanotechnology
New technology for producing materials that form extremely tiny particles is leading to
very promising imaging tests that can more accurately show the location of tumors. It
also is aiding the development of new ways to deliver drugs more specifically and
effectively to cancer cells.
Hyperlinks
1. www.cancer.org/cancer/screening/american-cancer-society-guidelines-for-the-
14
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
early-detection-of-cancer.html
References
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2011.pdf on June 8, 2012.
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
15
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Ancient physicians and surgeons knew that cancer would usually come back after it was
surgically removed. The Roman physician Celsus wrote, “After excision, even when a
scar has formed, none the less the disease has returned.”
Galen was a 2nd-century Greek doctor whose books were preserved for centuries. He
was thought to be the highest medical authority for over a thousand years. Galen
viewed cancer much as Hippocrates had, and considered the patient incurable after a
diagnosis of cancer had been made. His views set the pattern for cancer management
for centuries.
Even though medicine progressed and flourished in some ancient civilizations, there
was little progress in cancer treatment. The approach to cancer was Hippocratic (or
Galenic) for the most part. To some extent the belief that cancer cannot be cured has
persisted even into the 21st century. This has served to fuel the fear people have of the
disease. Some people, even today, consider all cancer incurable and put off seeing a
doctor until it’s too late for optimal treatment.
Cancer treatment has gone through a slow process of development. The ancients
recognized that there was no curative treatment once a cancer had spread, and that
intervention might be more harmful than no treatment at all. Galen did write about
surgical cures for breast cancer if the tumor could be completely removed at an early
stage. Surgery then was very primitive with many complications, including blood loss. It
wasn’t until the 19th and early 20th centuries that major advances were made in general
surgery and cancer surgery.
There were great surgeons before the discovery of anesthesia. John Hunter, Astley
Cooper, and John Warren achieved lasting acclaim for their swift and precise surgery.
But when anesthesia became available in 1846, the work advanced so rapidly that the
next hundred years became known as “the century of the surgeon.”
Three surgeons stand out because of their contributions to the art and science of cancer
surgery: Bilroth in Germany, Handley in London, and Halsted in Baltimore. Their work
led to “cancer operations” designed to remove the entire tumor along with the lymph
nodes in the region where the tumor was located.
16
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
in part on that of W. Sampson Handley, the London surgeon who believed that cancer
spread outward by invasion from the original growth. (The general concept of the radical
mastectomy can be traced all the way back to Lorenz Heister, a German who wrote
about his ideas for mastectomy and lumpectomy in his book, Chirurgie, published in
1719.)
Halsted did not believe that cancers usually spread through the bloodstream: “Although
it undoubtedly occurs, I am not sure that I have observed from breast cancer,
metastasis which seemed definitely to have been conveyed by way of the blood
vessels.” He believed that adequate local removal of the cancer would cure it – if the
cancer later appeared elsewhere, it was a new process. That belief led him to develop
the radical mastectomy for breast cancer. This became the basis of cancer surgery for
almost a century. Then, in the 1970s, modern clinical trials demonstrated that less
extensive surgery is equally effective for most women with breast cancer. Today, a
radical mastectomy is almost never done and the “modified radical mastectomy” is
performed less frequently than before. Most women with breast cancer now have the
primary tumor removed (lumpectomy), and then have radiation therapy.
At the same time Halsted and Handley were developing their radical operations, another
surgeon was asking, “What is it that decides which organs shall suffer in a case of
disseminated cancer?” Stephen Paget, an English surgeon, concluded that cancer cells
spread by way of the bloodstream to all organs in the body but were able to grow only in
a few organs. In a brilliant leap of logic he drew an analogy between cancer metastasis
and seeds that “are carried in all directions, but they can only live and grow if they fall
on congenial soil.”
Paget’s conclusion that cells from a primary tumor spread through the bloodstream but
could grow only in certain, and not all, organs was an accurate and highly sophisticated
hypothesis that was confirmed by the techniques of modern cellular and molecular
biology almost a hundred years later. This understanding of metastasis became a key
element in recognizing the limitations of cancer surgery. It eventually allowed doctors to
develop systemic treatments used after surgery to destroy cells that had spread
throughout the body so that they could use less mutilating operations in treating many
types of cancer. Today these systemic treatments may also be used before surgery.
During the final decades of the 20th century, surgeons developed greater technical
expertise in minimizing the amounts of normal tissue removed during cancer operations.
Like the trend from radical mastectomy to lumpectomy, progress was also made in
removing bone and soft tissue tumors of the arms and legs without the need for
amputation in most cases, and in avoiding a colostomy for most patients with rectal
cancer. This progress depended not only on understanding cancer better as a disease
and on better surgical instruments, but also on combining surgery with chemotherapy
17
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
and/or radiation.
Until near the end of the 20th century, diagnosing cancer often required “exploratory
surgery” to open the abdomen (belly) or chest so the surgeon could take tissue samples
to be tested for cancer. Starting in the 1970s, progress in imaging tests such as
ultrasound (sonography), computed tomography (CT scans), magnetic resonance
imaging (MRI scans), and positron emission tomography (PET scans) have replaced
many exploratory operations. CT scans and ultrasound can also be used to guide
biopsy needles into tumors.
Today, doctors use instruments with fiberoptic technology and miniature video cameras
to look inside the body. Surgeons can operate using special surgical instruments
through narrow tubes put into small cuts in the skin. These instruments can be used to
look and work inside the abdomen (laparoscopic surgery) or chest (thorascopic
surgery). A similar instrument, the endoscope, can be used to remove some tumors in
the colon, esophagus, or bladder by entering through natural body openings such as the
mouth or anus.
Less invasive ways of destroying tumors without removing them are being studied
and/or used. Cryosurgery (also called cryotherapy or cryoablation) uses liquid nitrogen
spray or a very cold probe to freeze and kill abnormal cells. Lasers can be used to cut
through tissue (instead of using a scalpel) or to vaporize (burn and destroy) cancers of
the cervix, larynx (voice box), liver, rectum, skin, and other organs. Radiofrequency
ablation transmits radio waves to a small antenna placed in the tumor to kill cancer cells
by heating them.
Robotic surgery
This term refers to manipulation of surgical instruments remotely by robot arms and
other devices controlled by a surgeon. Robotic systems have been used for several
types of cancer surgery; radical prostatectomy is among the most common uses in
surgical oncology. As mechanical and computer technology improve, some researchers
expect future systems will be able to remove tumors more completely and with less
surgical trauma.
Hyperlinks
18
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
1. www.cancer.org/cancer/types/breast-cancer.html
2. www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-
trials.html
3. www.cancer.org/cancer/managing-cancer/treatment-
types/surgery/ostomies/colostomy.html
4. www.cancer.org/cancer/types/colon-rectal-cancer.html
5. www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/imaging-radiology-
tests-for-cancer.html
6. www.cancer.org/cancer/types/colon-rectal-cancer.html
7. www.cancer.org/cancer/types/esophagus-cancer.html
8. www.cancer.org/cancer/types/bladder-cancer.html
9. www.cancer.org/cancer/types/cervical-cancer.html
10. www.cancer.org/cancer/types/laryngeal-and-hypopharyngeal-cancer.html
11. www.cancer.org/cancer/types/liver-cancer.html
12. www.cancer.org/cancer/types/colon-rectal-cancer.html
13. www.cancer.org/cancer/types/skin-cancer.html
References
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research
Advances in Cancer Treatment, Prevention and Screening. Accessed at
www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_20
09.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2011.pdf on June 8, 2012.
19
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 1. Cancer.
2011;117(5):1097-1102.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 2. Cancer.
2011;117(12):2811-2820.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. Cancer.
2012;118(4):1155-1168.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. Cancer.
2012;118(20):4914-4928.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
Harvey AM. Early contributions to the surgery of cancer: William S. Halsted, Hugh H.
Young and John G. Clark. Johns Hopkins Med J. 1974;135:399-417.
20
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Because the breast was “held in control” by the ovaries, Beatson decided to test
removal of the ovaries (called oophorectomy) in advanced breast cancer. He found that
oophorectomy often resulted in improvement for breast cancer patients. He also
suspected that “the ovaries may be the exciting cause of carcinoma” of the breast. He
had discovered the stimulating effect of the female ovarian hormone (estrogen) on
breast cancer, even before the hormone itself was discovered. His work provided a
foundation for the modern use of hormone therapy, such as tamoxifen and the
aromatase inhibitors, to treat or prevent breast cancer.
A half century after Beatson’s discovery, Charles Huggins, a urologist at the University
of Chicago, reported dramatic regression of metastatic prostate cancer after the
testicles were removed. Later, drugs that blocked male hormones were found to be
effective treatment for prostate cancer.
Hyperlinks
1. www.cancer.org/cancer/types/breast-cancer.html
2. www.cancer.org/cancer/types/prostate-cancer.html
References
21
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research
Advances in Cancer Treatment, Prevention and Screening. Accessed at
www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_20
09.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2011.pdf on June 8, 2012.
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. Cancer.
2012;118(4):1155-1168.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. Cancer.
2012;118(20):4914-4928.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
22
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
In 1901 Roentgen received the first Nobel Prize awarded in physics. Radiation therapy
began with radium and with relatively low-voltage diagnostic machines. In France, a
major breakthrough took place when it was discovered that daily doses of radiation over
several weeks greatly improved the patient’s chance for a cure. The methods and the
machines that deliver radiation therapy have steadily improved since then.
At the beginning of the 20th century, shortly after radiation began to be used for
diagnosis and therapy, it was discovered that radiation could cause cancer as well as
cure it. Many early radiologists used the skin of their arms to test the strength of
radiation from their radiotherapy machines, looking for a dose that would produce a pink
reaction (erythema) which looked like sunburn. They called this the “erythema dose,”
and this was considered an estimate of the proper daily fraction of radiation. It’s no
surprise that many of them developed leukemia from regularly exposing themselves to
radiation.
Advances in radiation physics and computer technology during the last quarter of the
20th century made it possible to aim radiation more precisely. Conformal radiation
therapy (CRT) uses CT images and special computers to very precisely map the
location of a cancer in 3 dimensions. The patient is fitted with a plastic mold or cast to
keep the body part still and in the same position for each treatment. The radiation
beams are matched to the shape of the tumor and delivered to the tumor from several
directions. Intensity-modulated radiation therapy (IMRT) is like CRT, but along with
aiming photon beams from several directions, the intensity (strength) of the beams can
be adjusted. This gives even more control in decreasing the radiation reaching normal
tissue while delivering a high dose to the cancer.
A related technique, conformal proton beam radiation therapy, uses a similar approach
to focusing radiation on the cancer. But instead of using x-rays, this technique uses
proton beams. Protons are parts of atoms that cause little damage to tissues they pass
through but are very effective in killing cells at the end of their path. This means that
proton beam radiation can deliver more radiation to the cancer while possibly reducing
23
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Stereotactic radiosurgery and stereotactic radiation therapy are terms that describe
several techniques used to deliver a large, precise radiation dose to a small tumor. The
term surgery may be confusing because no cutting is actually done. The most common
site treated with this radiation technique is the brain. A linear accelerator, or special
machines such as the Gamma Knife or CyberKnife, can be used to deliver this
treatment.
Chemical modifiers or radiosensitizers are substances that make cancer more sensitive
to radiation. The goal of research into these types of substances is to develop agents
that will make the tumor more sensitive without affecting normal tissues. Researchers
are also looking for substances that may help protect normal cells from radiation.
Hyperlinks
1. www.cancer.org/cancer/risk-prevention/radiation-exposure.html
References
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research
Advances in Cancer Treatment, Prevention and Screening. Accessed at
www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_20
09.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
24
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2011.pdf on June 8, 2012.
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. Cancer.
2012;118(20):4914-4928.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
Not long after the discovery of nitrogen mustard, Sidney Farber of Boston demonstrated
25
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
that aminopterin, a compound related to the vitamin folic acid, produced remissions in
children with acute leukemia. Aminopterin blocked a critical chemical reaction needed
for DNA replication. That drug was the predecessor of methotrexate, a cancer treatment
drug used commonly today. Since then, other researchers discovered drugs that block
different functions in cell growth and replication. The era of chemotherapy had begun.
Metastatic cancer was first cured in 1956 when methotrexate was used to treat a rare
tumor called choriocarcinoma. Over the years, chemotherapy drugs (chemo) have
successfully treated many people with cancer. Long-term remissions and even cures of
many patients with Hodgkin disease and childhood ALL (acute lymphoblastic leukemia)
treated with chemo were first reported during the 1960s. Cures of testicular cancer were
seen during the next decade. Many other cancers can be controlled with chemo for long
periods of time, even if they are not cured. Today, several approaches are available to
improve the activity and reduce the side effects of chemo. These include:
Early in the 20th century, only cancers small and localized enough to be completely
removed by surgery were curable. Later, radiation was used after surgery to control
small tumor growths that were not surgically removed. Finally, chemotherapy was
added to destroy small tumor growths that had spread beyond the reach of the surgeon
and radiotherapist. Chemo used after surgery to destroy any remaining cancer cells in
the body is called adjuvant therapy. Adjuvant therapy was tested first in breast cancer
and found to be effective. It was later used in colon cancer, testicular cancer, and
others.
A major discovery was the advantage of using multiple chemotherapy drugs (known as
combination chemotherapy) over single agents. Some types of very fast-growing
leukemia and lymphoma (tumors involving the cells of the bone marrow and lymph
nodes, respectively) responded very well to combination chemo, and clinical trials led to
gradual improvement of the drug combinations used. Many of these tumors can be
cured today by appropriate combination chemotherapy.
The approach to patient treatment has become more scientific with the introduction of
26
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
clinical trials on a wide basis throughout the world. Clinical trials compare new
treatments to standard treatments and contribute to a better understanding of treatment
benefits and risks. They are used to test theories about cancer learned in the basic
science laboratory and also test ideas drawn from the clinical observations on cancer
patients. They are necessary for continued progress.
Hyperlinks
1. www.cancer.org/cancer/types/lymphoma.html
2. www.cancer.org/cancer/types/leukemia-in-children.html
3. www.cancer.org/cancer/types/hodgkin-lymphoma.html
4. www.cancer.org/cancer/types/testicular-cancer.html
5. www.cancer.org/cancer/types/breast-cancer.html
6. www.cancer.org/cancer/types/colon-rectal-cancer.html
7. www.cancer.org/cancer/types/leukemia.html
8. www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-
trials.html
References
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research
Advances in Cancer Treatment, Prevention and Screening. Accessed at
www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_20
09.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2011.pdf on June 8, 2012.
27
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631 on June 7,
2012.
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. Cancer.
2012;118(20):4914-4928.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
Better understanding of the biology of cancer cells has led to the development of
biologic agents that mimic some of the natural signals that the body uses to control cell
growth. Clinical trials have shown that this cancer treatment, called biological response
modifier (BRM) therapy, biologic therapy, biotherapy, or immunotherapy, is effective for
many types of cancer.
Some of these biologic agents, which occur naturally in the body, can now be made in
the lab. Examples are interferons, interleukins, and other cytokines. These agents are
given to patients to imitate or influence the natural immune response. They do this
either by directly altering the cancer cell growth or by acting indirectly to help healthy
cells control the cancer.
One of the most exciting applications of biologic therapy has come from identifying
certain tumor targets, called antigens, and aiming an antibody at these targets. This
method was first used to find tumors and diagnose cancer and more recently has been
28
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
used to destroy cancer cells. Using technology that was first developed during the
1970s, scientists can mass-produce monoclonal antibodies that are specifically targeted
to chemical components of cancer cells. Refinements to these methods, using
recombinant DNA technology, have improved the effectiveness and decreased the side
effects of these treatments. The first therapeutic monoclonal antibodies, rituximab
(Rituxan) and trastuzumab (Herceptin) were approved during the late 1990s to treat
lymphoma and breast cancer, respectively. Monoclonal antibodies now are routinely
used to treat certain cancers, and many more are being studied.
Scientists are also studying vaccines that boost the body’s immune response to cancer
cells. In 2010, the FDA approved sipuleucel-T (Provenge), a cancer vaccine for
metastatic hormone-refractory prostate cancer (prostate cancer that has spread and is
no longer responding to hormone treatment). Unlike a preventive vaccine, which is
given to prevent disease, Provenge boosts the immune system’s ability to attack cancer
cells in the body. This treatment has been shown to help certain men with prostate
cancer live longer, though it does not cure the disease. It represents an important step
forward in cancer treatment.
Drugs aimed at specific immune checkpoints are being developed to help the immune
system better kill cancer cells.
Hyperlinks
1. www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-
trials.html
2. www.cancer.org/cancer/types/lymphoma.html
3. www.cancer.org/cancer/types/breast-cancer.html
4. www.cancer.org/cancer/types/prostate-cancer.html
References
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research
Advances in Cancer Treatment, Prevention and Screening. Accessed at
www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_20
09.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
29
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2011.pdf on June 8, 2012.
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part
5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part
6. Cancer. 2013;119(23):4058-4082.
Until the late 1990s nearly all drugs used in cancer treatment (with the exception of
30
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
hormone treatments) worked by killing cells that were in the process of replicating their
DNA and dividing to form 2 new cells. These chemotherapy drugs also killed some
normal cells but had a greater effect on cancer cells.
Targeted therapies work by influencing the processes that control growth, division, and
spread of cancer cells, as well as the signals that cause cancer cells to die naturally (the
way normal cells do when they are damaged or old). Targeted therapies work in several
ways.
Growth factors are hormone-like substances that help tell cells when to grow and divide.
Their role in fetal growth and repair of injured tissue was first recognized in the 1960s.
Later it was realized that abnormal forms of growth factors or abnormally high levels of
growth factors contribute to the growth and spread of cancer cells. Researchers have
also started to understand how cells recognize and respond to these factors, and how
that can lead to signals inside the cells that cause the abnormal features found in
cancer cells. Changes in these signal pathways have also been identified as a cause of
the abnormal behavior of cancer cells.
During the 1980s, scientists found that many of the growth factors and other substances
responsible for recognizing and responding to growth factors are actually products of
oncogenes. Among the earliest targeted therapies that block growth signals are
trastuzumab (Herceptin), gefitinib (Iressa), imatinib (Gleevec), and cetuximab (Erbitux).
Many others are available today.
Angiogenesis inhibitors
Angiogenesis is the creation of new blood vessels. The term comes from 2 Greek
words: angio, meaning “blood vessel,” and genesis, meaning “beginning.” Normally, this
is a healthy process. New blood vessels, for instance, help the body heal wounds and
repair damaged tissues. But in a person with cancer, this same process creates new,
very small blood vessels that give a tumor its own blood supply and allow it to grow.
Anti-angiogenesis agents are types of targeted therapy that use drugs or other
substances to stop tumors from making the new blood vessels they need to keep
growing. This concept was first proposed by Judah Folkman in the early 1970s, but it
wasn’t until 2004 that the first angiogenesis inhibitor, bevacizumab (Avastin), was
approved. Currently used to treat advanced colorectal, kidney, and lung cancers,
bevacizumab is being studied as treatment for many other types of cancer, too. And
many new drugs that block angiogenesis have become available since 2004.
31
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Apoptosis-inducing drugs
Apoptosis is a natural process through which cells with DNA too damaged to repair –
such as cancer cells – can be forced to die. Many anti-cancer treatments (including
radiation and chemo) cause cell changes that eventually lead to apoptosis. But targeted
drugs in this group are different, because they are aimed specifically at the cell
substances that control cell survival and death.
As more is learned about the molecular biology of cancer, researchers will have more
targets for their new drugs. Along with more monoclonal antibodies and small signaling
pathway inhibitors, researchers are developing new classes of molecules such as
antisense oligodeoxynucleotides and small interfering RNA (siRNA). Research is being
done to develop targeted drugs that are aimed at proteins produced by specific gene
mutations in cancer cells, too.
Researchers are looking for gene mutations that cause some patients to respond better
to certain drugs.
Hyperlinks
1. www.cancer.org/cancer/types/colon-rectal-cancer.html
2. www.cancer.org/cancer/types/kidney-cancer.html
3. www.cancer.org/cancer/types/lung-cancer.html
References
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research
Advances in Cancer Treatment, Prevention and Screening. Accessed at
www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_20
09.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
32
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Because more people are surviving cancer, more attention is focused on the quality of
life and long-term outcomes of these cancer survivors. Behavioral researchers are
working to learn more about the problems survivors face. Some of these problems are
medical, such as permanent side effects of treatment, the possibility of second cancers
caused by treatment, and the need for long-term treatment and medical follow-up. Other
problems are emotional or social challenges, like getting health insurance,
discrimination by employers, relationship changes that may result from life-threatening
illness, or learning to live with the possibility of cancer coming back.
Cancer was once a word that people were afraid to speak in public, and people rarely
admitted to being a cancer survivor. Now, many celebrities and national leaders very
openly discuss and share their cancer experiences. The view that cancer cannot be
cured and the fears that have historically been attached to the disease are slowly
changing.
33
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
References
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research
Advances in Cancer Treatment, Prevention and Screening. Accessed at
www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_20
09.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual
Report on Progress Against Cancer. Accessed at
www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Adv
ances/CCA_2011.pdf on June 8, 2012.
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J
Med. 2012;366(23):2207-2214.
Written by
Our team is made up of doctors and oncology certified nurses with deep knowledge of
cancer care as well as journalists, editors, and translators with extensive experience in
medical writing.
American Cancer Society medical information is copyrighted material. For reprint
34
American Cancer Society cancer.org | 1.800.227.2345
____________________________________________________________________________________
cancer.org | 1.800.227.2345
35